The ACHIEVE study is looking at a medicine for patients with kidney disease who receive dialysis. These patients are at risk of developing cardiovascular complications [heart failure, high blood pressure and strokes] and there are few medications available to reduce this risk.
The study will test the effectiveness and safety of a medicine called Spironolactone, previously not available to patients with Kidney Disease.
Participants will be allocated to one of two groups. One group will receive the trial medication (Spironolactone), the other will receive a placebo, with no active substances. This is to see if patients taking Spironolactone therapy are doing better compared to those who do not receive the active medication.
You can read more about the study here
In Aberdeen, we have recently had our first participants join the research! We want to say thanks to them for taking part and to the local research team who run the project here.